BioRestorative's Stem Cell Therapy for Back Pain Nears Key Trial Results

BioRestorative Therapies, Inc. (BRTX) has made steady progress in its regenerative medicine pipeline over the past year. The company, which specialises in stem cell-based treatments, recently completed patient enrolment for its Phase 2 trial of BRTX-100—a therapy targeting chronic lower back pain caused by degenerative disc disease. CEO Lance Alstodt also discussed these advancements in a recent interview with The Big Biz Show, reaching audiences across TV, radio, and digital platforms.

The company's lead candidate, BRTX-100, is currently under investigation in an FDA-approved Phase 2 trial for chronic lumbar disc disease. Enrolment for this study wrapped up in the final quarter of 2025, with topline results anticipated in early 2026. The trial remains active, awaiting full data analysis and further review by the FDA.

Beyond lumbar pain, BRTX-100 has also secured FDA Investigational New Drug (IND) clearance for treating chronic cervical discogenic pain. This expansion broadens the therapy's potential applications in degenerative spinal conditions.

In parallel, BioRestorative is advancing its Metabolic Program, ThermoStem. This initiative focuses on developing cell-based treatments for obesity and metabolic disorders, using stem cells derived from brown adipose tissue. The company is also exploring ways to widen its commercial reach, including a new line of biologic aesthetic products.

BioRestorative already operates a BioCosmeceutical platform, offering a proprietary serum designed to reduce fine lines and wrinkles. The firm has signalled plans to grow this segment, potentially introducing additional cell-based biologic therapies and cosmeceuticals.

During his interview on The Big Biz Show, CEO Lance Alstodt highlighted key milestones in the company's clinical and regulatory journey. He also touched on future commercial opportunities, though the company noted that forward-looking statements carry inherent risks and uncertainties.

Investors seeking further details can contact Stephen Kilmer, the company's investor relations representative, via phone at (646) 274-3580 or email at [email protected].

BioRestorative Therapies continues to focus on its Phase 2 trial for BRTX-100, with results due in early 2026. The company's broader pipeline includes metabolic therapies and aesthetic products, reflecting its strategy to diversify within regenerative medicine. Progress remains tied to regulatory reviews and clinical outcomes in the coming months.